Dr Reddy’s Laboratories (RDY) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dr. Reddy’s Laboratories has received a Form 483 with seven observations following a recent USFDA inspection at their API manufacturing facility in Hyderabad. The company plans to address these observations within the specified timeline, aiming to maintain compliance and operational standards. This development is crucial for investors monitoring the company’s regulatory adherence and potential impact on stock performance.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.